VRTX (Vertex Corp) Forward P/S Multiple

Vertex Pharmaceuticals represents a defensive asset that is completely independent of economic cycles. The projected P/S multiple confirms this stability, and 8.30 captures the magnitude of this parameter. Business resilience is based on the absence of sales seasonality for life-saving medications. Meanwhile, the risk of dependence on cystic fibrosis therapy is mitigated by the development of genetic engineering and an innovative pipeline.

Vertex - VRTX Forward P/S Multiple (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for Vertex Corp (VRTX)

- market price and analyst price targets:

Price Chart Vertex|VRTX - Forecast Levels Chart

- business market valuation indicators:

Market Capitalization Vertex Corp|VRTX - Value Adjusted for Debt and Cash

- issuer book value statistics:

Book Value per Share Vertex Pharmaceuticals|VRTX - Book Capitalization|Market Value to Book Value Ratio vrtx.com|VRTX - Aggregate Asset Value

- debt and solvency information:

- financial results and valuation multiples details:

VRTX - Final Profit|Future Profit Vertex Pharmaceuticals|VRTX - Market Price to Net Income Ratio|Forward P/E Multiple Vertex Pharmaceuticals Inc.|VRTX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Vertex Corp|VRTX - Operating profit before amortization|Net earnings per share for the last 12 months Vertex Pharmaceuticals|VRTX - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months vrtx.com|VRTX - Earnings per share trend in current year|Earnings growth forecast for next year Vertex Pharmaceuticals

- total revenue and sales volume data:

VRTX - Company Sales Revenue|Projected Sales Volume Vertex|VRTX - P/S Multiple|Price-to-Projected Revenue Ratio Vertex Corp

Fundamental company analysis:Vertex (VRTX)

To select high-quality assets, an investor must exclude overvalued securities to ensure a sufficient margin of safety for their capital. The forward P/S measures the market value of Vertex Pharmaceuticals (VRTX) relative to its expected revenue, which currently stands at 8.30. Given the exclusivity of high-cost cystic fibrosis treatments, the projected P/S valuation on the GURU.Markets platform allows investors to track the risk of overpaying for the company's monopoly position in the orphan disease market.

Who Vertex Pharmaceuticals competes with

Price-to-Projected Revenue Ratio Alnylam ALNY|INSM (Insmed Inc.) - Future Price to Revenue|United Therapeutics Corp. - Forward P/S Multiple|Forward Price to Sales BMRN (BioMarin Corp)|BBIO: Forward P/S Multiple|BGM Group (BGM) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Cogent Biosciences, Inc.|XERS: Forward Price to Sales|Price-to-Projected Revenue Ratio Keros Pharma (KROS)|Forward Price-to-Revenue Multiple Arcturus Corp ARCT|Forward P/S Multiple ETON (Eton Pharmaceuticals)|Forward P/S Multiple kamada.com KMDA|FULC: Forward Price-to-Revenue Multiple|ABEO: Price-to-Projected Revenue Ratio|MREO: Forward P/S Multiple|Market Cap to Future Revenue Ratio Protalix BioTherapeutics, Inc (PLX)|Price-to-Projected Revenue Ratio Pliant Therapeutics Inc|APLT: Forward Price to Sales|Forward Price-to-Revenue Multiple RNTX (Rein Therapeutics)|Price to Expected Revenue Ratio GELS|Forward P/S Multiple AYTU (Aytu BioPharma)|Chemomab Therapeutics Ltd (CMMB) - Market Cap to Future Revenue Ratio|SRXH: Forward Price-to-Revenue Multiple|PLRZ (Polyrizon Ltd) - Market Cap to Projected Revenue|AEZS (zentaris.com) - Forward Price-to-Revenue Multiple|Cyclo Therapeutics Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Inozyme Pharma Inc.|Reneo Pharmaceuticals, Inc - Future Price to Revenue|Forward P/S Multiple CSCI